Proinflammatory markers

Proinflammatory markers are a diverse group of signaling molecules, including cytokines, chemokines, enzymes, and acute-phase proteins, that initiate and sustain the host's inflammatory response to injury, infection, or stress (MDPI, 2024). Major members such as Tumor necrosis factor-alpha (TNF-α), Interleukin-1 (IL-1), and Interleukin-6 (IL-6) act as primary mediators that activate cellular pathways like NF-κB and JAK/STAT, leading to the recruitment of immune cells and the further production of inflammatory factors (Frontiers, 2025; PMC, 2025). While essential for acute defense and tissue repair, the chronic or dysregulated expression of these markers is a defining feature of many pathological states, including rheumatoid arthritis, inflammatory bowel disease, and neurodegenerative disorders such as Alzheimer's disease (Frontiers, 2025; ResearchGate, 2025). Therapeutic management involves the use of biologics to sequester specific cytokines, receptor antagonists to prevent signal transduction, and small molecule inhibitors that target upstream regulatory enzymes like cyclooxygenase-2 (COX-2) (MDPI, 2024). Monitoring these markers in serum or tissue serves as a critical clinical tool for assessing disease severity and evaluating the effectiveness of anti-inflammatory interventions (medRxiv, 2025; PMC, 2025).

Other names

Pro-inflammatory mediatorsInflammatory markersPro-inflammatory cytokinesInflammatory signaling moleculesSystemic inflammatory markers

Drugs targeting proinflammatory markers typically function by neutralizing circulating mediators using monoclonal antibodies, blocking cognitive receptors through receptor antagonism, or inhibiting the intracellular signaling pathways (e.g., JAK/STAT) and enzymatic activities (e.g., COX-2) responsible for their synthesis and pathological effects (MDPI, 2024; ResearchGate, 2025).